For the final five stable-growing cell lines, the corresponding patient tumor tissue of the pathology archive was re-evaluated and tested for the NAB2-STAT6 fusion by NGS to confirm the clinical and histological SFT diagnosis on a genetic level. This evidence concerns the gene NAB2 and neoplasm.